OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma [Yahoo! Finance]
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
OS Therapies Inc (NYSE: OSTX) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $19.00 price target on the stock.
OS Therapies to Host Analyst Day at NYSE on April 7, 2025 [Yahoo! Finance]